Skip to content
Clinical Trials – home

Copenhagen University Hospital

Verified siteinfo

Denmark Bispebjerg Bakke 23, 2400 Copenhagen, Denmark

  • 31 trials recruiting
  • Crohn's disease · Chronic coronary syndrome · Hypertrophic cardiomyopathy
  • Adults and children

About Specializations

Copenhagen University Hospital in Copenhagen, Denmark specialises in clinical trials of conditions such as Crohn's disease, Chronic coronary syndrome, Hypertrophic cardiomyopathy, Infection, and other specialisations. This site conducts important research.

Main research areas of the site

Neurocritical Care and Seizure Disorders

At Copenhagen University Hospital, the Department of Neuroanaesthesiology is involved in research on nervous system diseases, with a focus on severe seizure emergencies such as refractory status epilepticus. These studies are designed to assess whether new treatments can improve seizure control, safety, and tolerability when standard care is not enough.

  • Evaluating a new therapy added to standard anti-seizure treatment for refractory status epilepticus
  • Studying better ways to manage life-threatening seizure activity in emergency care

The research reflects a strong interest in improving outcomes for patients with urgent neurologic conditions.

Thoracic Oncology and Immunotherapy

This site also supports clinical research in neoplasms, especially malignant pleural mesothelioma. The trials are exploring whether immune-based treatments can help patients whose disease has progressed after earlier chemotherapy, with the goal of improving treatment effectiveness in a difficult-to-treat cancer.

  • Testing immunotherapy combinations for malignant pleural mesothelioma
  • Exploring whether adding a vaccine approach may strengthen cancer control

These studies contribute to the broader search for better options in advanced respiratory tract-related cancers.

Metabolic Health and Obesity Research

Clinical trials at Copenhagen University Hospital include work in nutritional and metabolic diseases, particularly obesity and related cardiovascular risk. The research aims to determine whether new treatments can support weight management while also improving long-term heart and vascular safety.

  • Assessing a potential treatment for people with overweight or obesity
  • Examining cardiovascular safety alongside metabolic benefit

These efforts highlight interest in therapies that address both body weight and broader metabolic health.

Rare Endocrine and Congenital Disorders

Research in congenital, hereditary, and neonatal diseases includes studies of congenital adrenal hyperplasia, a rare endocrine condition. The purpose of this work is to evaluate new treatment options that may better support disease control and improve quality of life for people living with this inherited disorder.

  • Investigating a new therapy for congenital adrenal hyperplasia
  • Advancing care for a rare inherited hormonal disorder

Across these trials, the site demonstrates a broad commitment to both rare disease research and clinically urgent conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Bispebjerg Bakke 232400 CopenhagenDenmark
Recruiting now
31 trials
Conditions studied
65
Partner status
Verified site

More sites in CopenhagenDenmark

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

58 clinical trials

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Discontinuing Acetylsalicylic Acid vs Continued Use in Patients ≥ 65 Years with Stable Chronic Coronary Syndrome

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Odense University Hospital

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Sepsis+1

Recruiting

Acetylcysteine for Adults with Acute Infection or Sepsis and Liver Dysfunction

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Rigshospitalet

Study of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Pediatric Research International GmbH
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.